|
摘要：
|
|
摘要：免疫耐受期是乙型肝炎病毒（hepatitis B virus，HBV）感染后的第一阶段，其一
般特征为HBV高水平复制、低炎症（血清丙氨酸氨基转移酶水平正常或轻微升高），
肝脏坏死、炎症及纤维化很少或无，因此各类指南并不主张在此阶段进行抗病毒治
疗。然而，近期有研究表明，处于免疫耐受期的患者存在肝功能损伤及肝癌发生的可
能，建议尽早开启抗病毒治疗以延缓疾病进展。免疫耐受期患者是否需要抗病毒治疗
仍具有极大的争议性，明确治疗时机对改善疾病预后具有重要意义。本文就目前HBV
感染免疫耐受期的有关治疗进展进行综述。
|
|
Abstract: Immune tolerance phase is the first stage after hepatitis B virus (HBV) infection.
It is generally characterized by high level of HBV replication, low inflammation (normal or
slightly elevated serum alanine aminotransferase), liver necrosis, inflammation and fibrosis
are rare, so various guidelines do not advocate antiviral therapy at this stage. However, recent
studies showed that patients in immune tolerance phase had the possibility of liver injury
and liver cancer. It is recommended to start antiviral therapy as soon as possible to delay the
progression of the disease. It is still controversial to evaluate whether patients need antiviral
therapy in this period, and it is of great significance to grasp the correct treatment opportunity
for patients to improve the prognosis of the disease. This paper reviewed the current progress
of immune tolerance of hepatitis B virus infection.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|